Evidence map›Paper›PMID 40543509›Full record

Trial reportCell reports. Medicine2025

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.

Caroline Laheurte, Laura Boullerot, Babacar Ndao, Marine Malfroy, Lise Queiroz, Phillippe Guillaume, Romain Loyon, Evan Seffar, Eleonore Gravelin, Adeline Renaudin and 9 more

Registry-linked trialAbstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07347210 (Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07347210 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of UCPVax Vaccine +/- Pembrolizumab Combined With Standard Treatment as Adjuvant Therapy in Patients With Unmethylated MGMT Glioblastoma: a Randomized Phase II Trial

TypeinterventionalSponsorCentre Hospitalier Universitaire de BesanconRan2026 to 2029Enrolled98ConditionsPrimary GlioblastomaArmsUCPVax, Pembrolizumab, Temozolomide
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Modular Vaccine Robots for Spatiotemporal Programming of the CD4Small (Weinheim an der Bergstrasse, Germany) · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Caroline LaheurteUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
Laura BoullerotUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
Babacar NdaoUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
Marine MalfroyUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
Lise QueirozLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland.
Phillippe GuillaumeLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland.
Romain LoyonUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
Evan SeffarComputational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Eleonore GravelinUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
Adeline RenaudinUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
Marion JacquinClinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France.
Aurélia MeurisseMethodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.
Dewi VernereyUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France; Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France.
François GhiringhelliDepartment of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Yann GodetUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France.
Raphael GenoletLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland; Department of Oncology UNIL CHUV, University Hospital of Lausanne, Lausanne, Switzerland.
Camilla JandusLudwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland; Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Geneva Center for Inflammation Research, Geneva, Switzerland.
Christophe BorgUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France; Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France; Department of Medical Oncology, University Hospital of Besançon, 25000 Besançon, France.
Olivier AdotéviUniversité Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, 25000 Besançon, France. Electronic address: olivier.adotevi@univ-fcomte.fr.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

The induction of an antitumor CD4

Indexed as

Antibody FormationCancer VaccinesEpitopesLung NeoplasmsTh1 CellsVaccines, SubunitCD4-Positive T-LymphocytesCytokinesFemaleHumansMaleMiddle AgedProtein Subunit VaccinesTelomeraseCancer VaccinesCytokinesEpitopesProtein Subunit VaccinesTelomeraseVaccines, Subunitantibody responsecancer vaccineCD4(+) T cellsepitope spreadinghelper peptidelung cancerpolyfunctional T celltelomerase

Identifiers

PMID40543509
PMCPMC12281370

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.